Outcomes of High-Dose-Rate Interstitial Brachytherapy in the Treatment of Locally Advanced Cervical Cancer: Long-term Results
| Autor: | Usama Mahmood, Nilam Ramsinghani, Philip J. DiSaia, Michael L. Berman, A.M. Nisar Syed, Melva Pinn-Bingham, Wen-Pin Chen, Ajmel A. Puthawala, Jeffrey V. Kuo, Krishnansu S. Tewari, Anil Sharma, Leslie M Randall-Whitis, Christine E. McLaren |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Cervical cancer
Cancer Research Chemotherapy medicine.medical_specialty Radiation business.industry medicine.medical_treatment Brachytherapy medicine.disease Article Surgery Radiation therapy Oncology medicine Carcinoma Medicine and Health Sciences Radiology Nuclear Medicine and imaging Radiology Stage (cooking) Young adult business Hydronephrosis |
| Zdroj: | Pinn-Bingham, Melva; Puthawala, Ajmel A; Syed, A.M. Nisar; Sharma, Anil; DiSaia, Philip; Berman, Michael; et al.(2013). Outcomes of High-Dose-Rate Interstitial Brachytherapy in the Treatment of Locally Advanced Cervical Cancer: Long-term Results. International Journal of Radiation Oncology*Biology*Physics, 85(3), 714-720. doi: 10.1016/j.ijrobp.2012.05.033. UC Irvine: Institute for Clinical and Translational Science. Retrieved from: http://www.escholarship.org/uc/item/22n2s66q |
| DOI: | 10.1016/j.ijrobp.2012.05.033. |
| Popis: | Purpose The purpose of this study was to determine locoregional control (LRC), disease-free survival (DFS), and toxicity of high-dose-rate interstitial brachytherapy (HDR-ISBT) in the treatment of locally advanced cervical cancer. Methods and Materials Between March 1996 and May 2009, 116 patients with cervical cancer were treated. Of these, 106 (91%) patients had advanced disease (International Federation of Gynecology and Obstetrics stage IIB-IVA). Ten patients had stage IB, 48 had stage II, 51 had stage III, and 7 had stage IVA disease. All patients were treated with a combination of external beam radiation therapy (EBRT) to the pelvis (5040 cGy) and 2 applications of HDR-ISBT to a dose of 3600 cGy to the implanted volume. Sixty-one percent of patients also received interstitial hyperthermia, and 94 (81%) patients received chemotherapy. Results Clinical LRC was achieved in 99 (85.3%) patients. Three-year DFS rates were 59%, 67%, 71%, and 57% for patients with stage IB, II, III, and IVA disease, respectively. The 5-year DFS and overall survival rates for the entire group were 60% and 44%, respectively. Acute and late toxicities were within acceptable limits. Conclusions Locally advanced cervical cancer patients for whom intracavitary BT is unsuitable can achieve excellent LRC and OS with a combination of EBRT and HDR-ISBT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|